Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biotechs license from big pharma

September 11, 2006 | A version of this story appeared in Volume 84, Issue 37

Anthera Pharmaceuticals has licensed the rights to a collection of phospholipase A2 (PLA2) inhibitors from Eli Lilly & Co. and the Japanese firm Shionogi. The PLA2 family of enzymes is involved in the arachidonic acid pathway of inflammation. Anthera intends to initiate clinical studies for the lead compound, A-001, as an early intervention therapy for acute chest syndrome in sickle cell patients. In a separate deal, Xanthus Pharmaceuticals has paid an undisclosed sum to Schering AG for the rights to a group of cancer compounds. The deal includes P2045, an 11-amino-acid peptide targeting tumors that overexpress somatostatin receptors; P2045 can be combined with rhenium-188 to deliver a targeted dose of radiation to tumors. The drug was originally developed by Xanthus researchers when they were at Diatide, a company that Schering acquired in 1999.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.